Human papillomavirus and cervical disease in adolescents

Clinical Obstetrics and Gynecology

Volumn 51, Issue 2, 2008, Pages 290-305

  Guido, Richard ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adolescent; Colposcopy; Cytology; HPV; Vaccination

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; HISTORY; HUMAN; NONHUMAN; PRACTICE GUIDELINE; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; COLPOSCOPY; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 43249122203     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318172d0dc     Document Type: Review

References (35)

1. Wallboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:9-12.
2. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003;8:930-934.
3. Woodman CB, Collins S, Winter H, et al. "Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. [see comment]." Lancet. 2001;357:1831-1836.
4. Ferenczy A, Bergeron C, RichArt RM. "Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections." Obstet Gynecol. 1989;74:950-954.
5. Roden RB, Lowy DR, Schiller JT. "Papillomavirus is resistant to desiccation." J Infect Dis. 1997;176:1076-1079.
6. Moscicki AB. "Impact of HPV infection in adolescent populations." J Adolesc Health. 2005;37(6 suppl):S3-S9.
7. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
8. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-1412.
9. Duggan MA, McGregor SE, Stuart GC. The natural history of CIN I lesions. Eur J Gynaecol Oncol. 1998;19:338-344.
10. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
11. Hewitt M, Devesa SS, Breen N. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004;39:270-278.
12. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Eng J Med. 2006;354:2645-2654.
13. Suzich JA, Ghim SL, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. 1995;92:11553-11557.
14. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
15. Stanley M. Prevention strategies against the human papillomavirus. Gynecologic Oncology. 2007;107:S19-S23.
16. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
17. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 viruslike particle vaccine against human papillomavirus types 16 and 18: follow-up from randomised control trial. Lancet. 2006;367:1247-1255.
18. Prescribing information for GARDASIL. Whitehouse Station (NJ): Merck & Co Inc; 2006. Available at: www.merck.com/product/usa/pi_circulars/g/ gardasil/gardasil_pi.pdf. Retrieved June 26, 2006.
19. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a meta-analysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol. 2001;185:308.
20. Sass MA. Use of a liquid-based, thinlayer Pap test in a community hospital. Impact on cytology performance and productivity. Acta Cytol. 2004;48:17.
21. Solomon D, Davey D, Kurman R. The 2001 Bethesda System, Terminology for reporting results of cervical cytology. JAMA. 2002;287:2114.
22. Sherman ME, Tabbara SO, Scott DR. "ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection. Mod Pathol. 1999;12:335.
23. ACOG Committee Opinion. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Number 330. Obstet Gynecol. 2006;107:963-968.
24. ACOG Practice Bulletin. Management of abnormal cervical cytology and histology. Number 66. Obstet Gynecol. 2005;106:645-664.
25. Saslow D, Runowicz CD, Solomon D. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342.
26. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489-498.
27. Samson SL, Bentley JR, Fahey TJ, et al. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol. 2005;105:325-332.
28. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100-2106.
29. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol. 2003;102:765.
30. Wright TC, Massad SL, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355.
31. Wright TC, Massad SL, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-345.
32. Guido R, Schiffman M, Solomon D, et al; ASCUS LSIL Triage Study (ALTS) Group. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003;188:1401-1405.
33. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intraepithelial lesions in young women. Lancet. 2006; 364:1678-1683.
34. Diaz-Montes TP, Farinola MA, Zahurak ML, et al. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol. 2006;104:366-371.
35. Robertson AJ, Anderson JM, Beck JS, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 1989;42:231-238.